Quick Answer
INOVIO PHARMACEUTICALS, INC. reported R&D Expense of $54.21 million for fiscal year 2025.
INOVIO PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $54.21M | -28.3% |
| 2024 | $75.62M | -12.8% |
| 2023 | $86.68M | -53.8% |
| 2022 | $187.65M | -24.7% |
| 2021 | $249.24M | +164.5% |
| 2020 | $94.25M | +7.1% |
| 2019 | $88.02M | -7.6% |
| 2018 | $95.26M | -3.4% |
| 2017 | $98.57M | +11.1% |
| 2016 | $88.71M | +53.5% |
| 2015 | $57.79M | +69.5% |
| 2014 | $34.10M | +59.6% |
| 2013 | $21.37M | +18.8% |
| 2012 | $17.98M | -10.2% |
| 2011 | $20.03M | +51.1% |
| 2010 | $13.26M | +40.9% |
| 2009 | $9.41M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.33M | -28.8% | -8.2% |
| June 30, 2025 | $14.52M | -37.1% | -9.8% |
| March 31, 2025 | $16.09M | -23.1% | -14.1% |
| September 30, 2024 | $18.73M | +20.8% | -18.9% |
| June 30, 2024 | $23.09M | -2.8% | +10.4% |
| March 31, 2024 | $20.91M | -30.7% | +34.9% |
| September 30, 2023 | $15.50M | -53.1% | -34.7% |
| June 30, 2023 | $23.74M | -57.9% | -21.3% |
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -28.3% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, INOVIO PHARMACEUTICALS, INC.’s r&d expense has grown by 476.2% (from $9.41 million to $54.21 million).
- The most recent figure is from INOVIO PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: